The Therapeutic Nanobody Profiler: characterising and predicting nanobody developability to improve therapeutic design
Gordon, G. L.; Gervasio, J.; Souders, C.; Deane, C. M.
Show abstract
Developability optimisation is an important step for successful biotherapeutic design. For monoclonal antibodies, developability is relatively well characterised. However, progress for novel biotherapeutics such as nanobodies is more limited. Differences in structural features between antibodies and nanobodies render current antibody computational methods unsuitable for direct application to nanobodies. Following the principles of the Therapeutic Antibody Profiler (TAP), we have built the Therapeutic Nanobody Profiler (TNP), an open-source computational tool for predicting nanobody developability. Tailored specifically for nanobodies, it accounts for their unique properties compared to conventional antibodies for more efficient development of this novel therapeutic format. We calibrate TNP metrics using the 36 currently available clinical-stage nanobody sequences. We also collected experimental developability data for 108 nanobodies and examine how these results are related to the TNP guidelines. TNP is available as a web application at opig.stats.ox.ac.uk/webapps/tnp.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.